Basel University Hospital, Dept. of Laboratory Medicine, Petersgraben 4, CH 4031 Basel, Switzerland.
Methods. 2012 Apr;56(4):494-9. doi: 10.1016/j.ymeth.2012.03.019. Epub 2012 Apr 6.
We compared the performance of the Meso Scale Diagnostics electrochemiluminescence (MSD) multiplex assay for t-tau and p-tau(231), originally developed for measurement of brain cell extract and tissue cultures, with the established standard method, the Innogenetics ELISA for total and p-tau(181). The methods were also clinically evaluated with 120 samples from our mono center population. The established Innogenetics ELISA procedures have been well optimized to measure patient samples in the normal and pathological range. Compared to the MSD they were superior in the limit of detection for total as well as p-tau. The obtained reference values for our normal controls were in the upper third of the published studies. Innogenetics tau, Innogenetics p-tau(181) and MSD t-tau differentiated the Alzheimer's (n=44) and minimal impairment group (MCI, n=39) from normal controls (n=37), but the MCI group was not statistically different from the normal controls. The MSD multiplex assay measured t-tau adequately but p-tau(231) could not differentiate normal from pathological results in CSF due to the high limit of detection. Both procedures however, have to be further standardized and complemented by adequate internal and external quality control schemes to qualify for routine analysis in a medical laboratory.
我们比较了 Meso Scale Diagnostics 电化学发光(MSD)多重分析试剂盒检测总 tau 和磷酸化 tau(231)(最初用于测量脑细胞提取物和组织培养物)的性能,该试剂盒与已建立的标准方法——Innogenetics ELISA 检测总 tau 和磷酸化 tau(181)。这两种方法还在我们的单中心人群中对 120 个样本进行了临床评估。Innogenetics ELISA 程序已经经过充分优化,可以在正常和病理范围内测量患者样本。与 MSD 相比,它们在检测总 tau 和磷酸化 tau 的检测限方面更具优势。我们正常对照组的参考值处于已发表研究的较高三分之一。Innogenetics tau、Innogenetics p-tau(181)和 MSD t-tau 能够区分阿尔茨海默病(n=44)和轻度认知障碍(MCI,n=39)与正常对照组(n=37),但 MCI 组与正常对照组在统计学上没有差异。MSD 多重分析试剂盒可以充分测量 t-tau,但由于检测限较高,p-tau(231)无法区分 CSF 中的正常和病理结果。然而,这两种方法都需要进一步标准化,并通过适当的内部和外部质量控制方案进行补充,以有资格在医学实验室进行常规分析。